Musk’s Neuralink Plans Speech Trial, Nonmedical Brain Implant

Neuralink Corp., the brain implant venture founded by Elon Musk, is gearing up to initiate a groundbreaking clinical trial in the United States this October. This trial aims to utilize Neuralink's innovative device to transform thoughts into text, paving the way for enhanced communication for individuals with speech impairments. Furthermore, the company aspires to implant its technology in healthy individuals by 2030, signifying a bold shift from the current focus of brain implant firms that primarily test their devices on patients with severe medical conditions. DJ Seo, the president of Neuralink, shared insights during a recent presentation at the Korea Foundation for Advanced Studies in Seoul. He projected, "We’re currently envisioning a world where in about 3 to 4 years, there will be someone who’s otherwise healthy who’s going to get a Neuralink." This trial is particularly notable as it aims to directly interpret brain signals related to speech. Seo emphasized, "If you’re imagining saying something, we would be able to pick that up." The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption for Neuralink, allowing the company to commence testing with an unapproved device. Currently, Neuralink is engaged in five other clinical trials, focusing on implants that enable users to control electronic devices such as computers and robotic arms. However, no commercial implants that can directly read speech from the brain are available to patients at this time. Neuralink is among several firms developing brain-computer interfaces that could facilitate direct communication between the brain and electronic devices, bypassing traditional methods of interaction. While the immediate goal is to improve the quality of life for those with medical conditions, the long-term vision extends to enhancing human capabilities broadly. During a Q&A session, Seo revealed that the company ultimately aims to produce consumer technology, which could revolutionize how individuals interact with AI platforms. Seo highlighted the potential of this technology to allow users to engage with advanced AI models at the speed of thought, conceivably receiving responses through devices like AirPods. "We think it’s actually possible to demonstrate abilities to speak to the latest AI model at the speed of thought, even faster than how you’re speaking," he said. Researchers have been exploring similar technologies to assist those affected by strokes or neurodegenerative diseases such as ALS, which impairs speech control while leaving cognitive functions intact. Neuralink's devices could enable direct transmission of a person’s intended speech to a computer. Recent studies have already shown that researchers can interpret thoughts directly from the brain, identifying what individuals wish to say or even what they imagine saying. Although the October start for the thought-to-text trial represents a slight delay from earlier timelines, Neuralink remains committed to its ambitious goals, which include potential treatments for blindness and Parkinson’s disease. The company envisions implanting devices in 20,000 individuals annually by 2031, although none of its devices are yet available for commercial use.